Index RUT
P/E -
EPS (ttm) -4.64
Insider Own 24.84%
Shs Outstand 34.21M
Perf Week 7.99%
Market Cap 1.36B
Forward P/E -
EPS next Y -2.02
Insider Trans -1.19%
Shs Float 28.19M
Perf Month -4.01%
Income -135.89M
PEG -
EPS next Q -1.23
Inst Own 75.11%
Short Float 25.52%
Perf Quarter 77.58%
Sales 17.45M
P/S 78.12
EPS this Y 7.16%
Inst Trans 1.81%
Short Ratio 9.30
Perf Half Y 130.21%
Book/sh 5.76
P/B 6.31
EPS next Y 52.89%
ROA -55.01%
Short Interest 7.20M
Perf Year 196.98%
Cash/sh 6.07
P/C 5.99
EPS next 5Y -
ROE -69.71%
52W Range 11.33 - 40.40
Perf YTD 79.51%
Dividend Est. -
P/FCF -
EPS past 5Y -132.82%
ROI -59.52%
52W High -10.02%
Beta 1.05
Dividend TTM -
Quick Ratio 6.85
Sales past 5Y -17.43%
Gross Margin 85.48%
52W Low 220.83%
ATR (14) 2.10
Dividend Ex-Date -
Current Ratio 6.93
EPS Y/Y TTM -80.72%
Oper. Margin -820.53%
RSI (14) 63.15
Volatility 5.32% 6.57%
Employees 244
Debt/Eq 0.16
Sales Y/Y TTM -32.42%
Profit Margin -778.89%
Recom 1.33
Target Price 52.33
Option/Short Yes / Yes
LT Debt/Eq 0.16
EPS Q/Q -157.80%
Payout -
Rel Volume 1.34
Prev Close 34.57
Sales Surprise 138.99%
EPS Surprise 4.53%
Sales Q/Q 30.76%
Earnings Feb 27 BMO
Avg Volume 773.50K
Price 36.35
SMA20 8.16%
SMA50 17.32%
SMA200 73.98%
Trades
Volume 1,033,264
Change 5.15%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Initiated
Goldman
Neutral
$19
Jul-18-23 Initiated
William Blair
Outperform
$44
May-18-23 Initiated
Guggenheim
Buy
Aug-01-22 Initiated
Barclays
Overweight
$40
Dec-21-21 Initiated
H.C. Wainwright
Buy
$40
Nov-23-21 Initiated
Oppenheimer
Outperform
$55
Nov-10-20 Initiated
Raymond James
Strong Buy
$39
Nov-10-20 Initiated
Ladenburg Thalmann
Buy
$42
Nov-10-20 Initiated
Jefferies
Buy
$35
Nov-10-20 Initiated
BofA Securities
Buy
$33
Mar-06-24 09:55AM
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
12:00PM
Loading…
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
(Thomson Reuters StreetEvents) +18.28%
06:34AM
06:00AM
Feb-22-24 08:00AM
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
03:32PM
Loading…
Dec-21-23 03:32PM
(Investor's Business Daily)
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
Aug-03-23 02:14PM
Aug-01-23 10:30PM
Jul-31-23 04:29PM
Jul-25-23 07:00AM
02:04PM
Loading…
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Jun-05-23 08:30AM
May-09-23 04:05PM
May-08-23 08:30AM
May-05-23 08:22AM
May-03-23 04:30PM
Apr-24-23 08:30AM
Apr-18-23 06:04AM
Apr-06-23 03:52PM
Mar-17-23 06:28AM
Mar-13-23 04:05PM
Mar-09-23 10:00AM
Mar-02-23 04:30PM
Feb-24-23 11:44AM
Jan-24-23 04:33AM
Dec-16-22 07:00AM
Dec-15-22 12:45PM
08:30AM
Dec-08-22 06:55AM
Nov-11-22 06:03AM
Nov-09-22 08:45AM
07:00AM
Oct-25-22 08:30AM
Oct-17-22 09:26AM
Oct-11-22 08:30AM
Oct-06-22 08:30AM
Sep-29-22 08:30AM
Sep-27-22 12:00PM
Sep-17-22 10:23AM
Sep-07-22 07:00AM
Aug-11-22 05:25PM
04:05PM
Aug-05-22 08:30AM
Jul-25-22 08:00AM
Jun-29-22 06:51AM
May-27-22 09:00AM
May-14-22 08:19AM
May-11-22 06:30AM
May-10-22 06:55PM
04:05PM
May-09-22 01:49PM
May-06-22 09:00AM
May-05-22 08:30AM
May-03-22 03:00PM
06:58AM
May-02-22 07:01AM
07:00AM
Apr-29-22 09:23PM
Apr-26-22 08:30AM
Apr-21-22 03:05AM
Mar-14-22 04:05PM
Mar-09-22 05:00PM
Feb-03-22 09:00AM
Feb-02-22 04:30PM
07:00AM
Jan-04-22 09:00AM
Nov-23-21 04:30PM
Nov-10-21 04:30PM
Nov-09-21 04:05PM
Nov-05-21 12:04PM
Nov-04-21 11:28AM
09:45AM
Nov-02-21 05:00PM
Oct-19-21 02:38PM
Oct-11-21 07:43PM
Aug-13-21 07:07AM
Aug-12-21 09:00AM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Azamian Bobak R. President/CEO and Board Chair Mar 18 '24 Sale 30.60 10,415 318,699 26,456 Mar 19 07:05 PM Neervannan Seshadri Chief Operating Officer Mar 18 '24 Sale 30.60 4,879 149,297 64,767 Mar 19 07:03 PM Mottiwala Aziz Chief Commercial Officer Mar 18 '24 Sale 30.60 4,766 145,840 54,075 Mar 19 07:08 PM Wahl Bryan General Counsel Mar 18 '24 Sale 30.60 4,436 135,742 40,951 Mar 19 07:05 PM Whitfield Dianne C. Chief Human Resources Officer Mar 18 '24 Sale 30.60 4,314 132,008 34,181 Mar 19 07:04 PM Azamian Bobak R. President/CEO and Board Chair Dec 27 '23 Sale 20.22 8,000 161,760 830,106 Dec 29 05:08 PM Azamian Bobak R. President/CEO and Board Chair Dec 20 '23 Sale 20.27 40,000 810,623 838,106 Dec 22 05:30 PM Trevejo Jose M. CHIEF MEDICAL OFFICER Dec 20 '23 Sale 20.00 2,252 45,040 2,251 Dec 22 05:32 PM Goldberg Andrew D. Director Dec 15 '23 Buy 18.96 1,000 18,960 3,000 Dec 19 06:30 PM Wahl Bryan General Counsel Nov 30 '23 Sale 16.31 8,356 136,286 31,966 Dec 01 04:55 PM Whitfield Dianne C. Chief Human Resources Officer Nov 30 '23 Sale 16.31 8,355 136,270 26,784 Dec 01 04:58 PM Whitfield Dianne C. Chief Human Resources Officer Nov 29 '23 Option Exercise 0.00 23,920 0 35,139 Dec 01 04:58 PM Wahl Bryan General Counsel Nov 29 '23 Option Exercise 0.00 23,920 0 40,322 Dec 01 04:55 PM Azamian Bobak R. President/CEO and Board Chair Nov 15 '23 Sale 18.37 8,000 146,933 878,106 Nov 17 04:50 PM Azamian Bobak R. President/CEO and Board Chair Oct 18 '23 Sale 13.24 8,000 105,920 886,106 Oct 20 04:41 PM Trevejo Jose M. CHIEF MEDICAL OFFICER Oct 05 '23 Sale 18.00 1,604 28,872 4,503 Oct 06 05:21 PM Azamian Bobak R. President/CEO and Board Chair Sep 20 '23 Sale 17.21 8,000 137,680 894,106 Sep 22 05:30 PM Azamian Bobak R. President/CEO and Board Chair Aug 23 '23 Sale 17.23 8,000 137,840 902,106 Aug 25 05:12 PM Lin Elizabeth Yeu Director Aug 15 '23 Buy 16.80 9,506 159,701 15,866 Aug 17 06:02 PM Azamian Bobak R. President/CEO and Board Chair Jul 19 '23 Sale 20.01 103,900 2,078,984 910,106 Jul 21 05:42 PM Mottiwala Aziz Chief Commercial Officer Jul 19 '23 Sale 20.05 2,400 48,120 45,806 Jul 21 05:46 PM Azamian Bobak R. President/CEO and Board Chair Jul 12 '23 Sale 17.35 9,000 156,150 1,014,006 Jul 14 04:40 PM Azamian Bobak R. President/CEO and Board Chair Jun 21 '23 Sale 18.63 8,000 149,040 1,023,006 Jun 23 04:29 PM Azamian Bobak R. President/CEO and Board Chair Jun 14 '23 Sale 18.58 9,000 167,220 1,031,006 Jun 16 04:48 PM Azamian Bobak R. President/CEO and Board Chair Jun 08 '23 Sale 20.01 3,100 62,031 1,040,006 Jun 12 05:40 PM Mottiwala Aziz Chief Commercial Officer Jun 08 '23 Sale 20.00 100 2,000 48,086 Jun 12 05:25 PM Mottiwala Aziz Chief Commercial Officer Jun 07 '23 Sale 19.34 2,500 48,350 48,186 Jun 08 07:16 PM Mottiwala Aziz Chief Commercial Officer Jun 06 '23 Sale 18.61 2,143 39,881 50,686 Jun 08 07:16 PM Azamian Bobak R. President/CEO and Board Chair May 17 '23 Sale 15.90 8,000 127,200 1,043,106 May 19 07:08 PM Azamian Bobak R. President/CEO and Board Chair May 10 '23 Sale 16.80 9,000 151,200 1,051,106 May 12 05:08 PM Azamian Bobak R. President/CEO and Board Chair May 01 '23 Sale 15.10 5,841 88,199 1,060,106 May 02 07:06 PM Azamian Bobak R. President/CEO and Board Chair Apr 28 '23 Sale 15.13 4,278 64,726 1,065,947 May 02 07:06 PM Azamian Bobak R. President/CEO and Board Chair Apr 21 '23 Sale 15.03 2,311 34,734 1,070,225 Apr 25 05:22 PM Greenstein Leonard M. Chief Financial Officer Apr 20 '23 Sale 14.02 5,000 70,100 26,785 Apr 21 05:53 PM Azamian Bobak R. President/CEO and Board Chair Apr 19 '23 Sale 13.60 8,000 108,800 1,072,536 Apr 21 05:49 PM
Index -
P/E -
EPS (ttm) -1.86
Insider Own 33.54%
Shs Outstand 54.94M
Perf Week -1.46%
Market Cap 75.06M
Forward P/E -
EPS next Y -0.98
Insider Trans -0.19%
Shs Float 36.95M
Perf Month -21.97%
Income -102.06M
PEG -
EPS next Q -0.36
Inst Own 20.93%
Short Float 3.28%
Perf Quarter 43.25%
Sales 0.00M
P/S -
EPS this Y 35.97%
Inst Trans -6.59%
Short Ratio 2.82
Perf Half Y 103.19%
Book/sh 2.03
P/B 0.67
EPS next Y 18.10%
ROA -51.80%
Short Interest 1.21M
Perf Year 39.18%
Cash/sh 2.06
P/C 0.66
EPS next 5Y -
ROE -65.29%
52W Range 0.58 - 1.79
Perf YTD 33.66%
Dividend Est. -
P/FCF -
EPS past 5Y -46.23%
ROI -76.05%
52W High -24.58%
Beta 1.29
Dividend TTM -
Quick Ratio 7.22
Sales past 5Y 0.00%
Gross Margin -
52W Low 134.74%
ATR (14) 0.17
Dividend Ex-Date -
Current Ratio 7.22
EPS Y/Y TTM 25.46%
Oper. Margin 0.00%
RSI (14) 49.06
Volatility 9.82% 12.70%
Employees 58
Debt/Eq 0.24
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 7.00
Option/Short Yes / Yes
LT Debt/Eq 0.21
EPS Q/Q 38.47%
Payout -
Rel Volume 0.43
Prev Close 1.31
Sales Surprise -
EPS Surprise 22.28%
Sales Q/Q -
Earnings Mar 04 BMO
Avg Volume 429.80K
Price 1.35
SMA20 -8.13%
SMA50 8.77%
SMA200 50.17%
Trades
Volume 185,410
Change 3.05%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-08-22 Downgrade
JP Morgan
Overweight → Neutral
Jan-19-22 Downgrade
Goldman
Buy → Neutral
$29 → $6
Jul-01-21 Initiated
Raymond James
Outperform
$29
Jun-15-21 Initiated
BTIG Research
Buy
$25
Mar-04-21 Upgrade
Goldman
Neutral → Buy
$28 → $30
Feb-04-21 Initiated
Guggenheim
Buy
$25
Jan-25-21 Initiated
Wedbush
Outperform
$26
Jan-04-21 Upgrade
JP Morgan
Neutral → Overweight
$25 → $35
Dec-11-20 Initiated
Citigroup
Neutral
$28
Aug-14-20 Downgrade
JP Morgan
Overweight → Neutral
$25
Jun-25-20 Downgrade
Goldman
Buy → Neutral
$28
Mar-25-20 Initiated
Chardan Capital Markets
Buy
$30
Mar-24-20 Initiated
JP Morgan
Overweight
$25
Mar-24-20 Initiated
Goldman
Buy
$27
Mar-24-20 Initiated
Cowen
Outperform
Show Previous Ratings
Mar-07-24 12:00PM
Mar-06-24 01:52PM
Mar-05-24 07:00AM
Mar-04-24 07:00AM
Feb-27-24 07:00AM
07:09PM
Loading…
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Dec-25-23 10:14PM
Dec-20-23 07:00AM
Nov-17-23 04:30PM
Nov-13-23 07:00AM
Oct-30-23 07:00AM
Oct-20-23 04:30PM
Sep-25-23 07:00AM
Aug-11-23 10:04AM
(American City Business Journals)
07:15AM
Loading…
Aug-07-23 07:15AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-24-23 12:37PM
(American City Business Journals) -5.31%
Jul-06-23 11:17AM
Jun-05-23 07:00AM
May-11-23 07:00AM
May-04-23 07:00AM
Apr-21-23 04:01PM
Apr-17-23 07:00AM
Mar-29-23 09:02AM
Mar-27-23 07:00AM
Mar-08-23 07:14AM
Mar-07-23 12:42AM
(Thomson Reuters StreetEvents)
07:00AM
Loading…
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-20-23 05:59PM
(American City Business Journals)
Feb-15-23 07:00AM
Jan-20-23 04:01PM
Jan-07-23 07:39AM
Dec-14-22 12:13PM
07:00AM
Nov-21-22 05:24AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:30AM
Oct-14-22 04:01PM
Oct-11-22 12:25PM
Oct-10-22 07:00AM
Sep-26-22 07:00AM
Aug-19-22 04:01PM
Aug-11-22 07:00AM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-28-22 07:30AM
Jul-21-22 04:01PM
Jul-12-22 08:19AM
Jul-06-22 07:00AM
Jun-09-22 07:30AM
Jun-08-22 07:30AM
Jun-01-22 10:19AM
(American City Business Journals)
07:30AM
May-20-22 04:01PM
May-18-22 07:00AM
May-16-22 07:00AM
May-09-22 07:00AM
May-04-22 10:55AM
(Simply Wall St.) +13.78%
May-03-22 02:13PM
May-02-22 04:01PM
Apr-22-22 04:01PM
Mar-29-22 07:00AM
Mar-28-22 07:00AM
Mar-15-22 11:22AM
(American City Business Journals)
11:12AM
07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Mar-01-22 07:00AM
Feb-24-22 07:00AM
Feb-11-22 11:00AM
Feb-01-22 12:49PM
Jan-31-22 07:00AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-17-21 07:00AM
Dec-08-21 02:35PM
(American City Business Journals)
07:00AM
Nov-30-21 11:08AM
Nov-19-21 04:00PM
Nov-12-21 05:51AM
Nov-09-21 07:00AM
Nov-04-21 07:00AM
Nov-01-21 03:05PM
Oct-28-21 07:00AM
Sep-29-21 04:42PM
Sep-27-21 07:00AM
Sep-17-21 04:01PM
Sep-07-21 07:00AM
Sep-02-21 07:00AM
Aug-05-21 07:00AM
Aug-04-21 09:00PM
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Forman Mark S CHIEF MEDICAL OFFICER Feb 13 '24 Sale 0.97 1,638 1,589 48,631 Feb 13 07:34 PM Borthwick Kathleen SVP, INTERIM CFO Feb 13 '24 Sale 0.97 1,470 1,426 28,466 Feb 13 07:36 PM Forman Mark S Chief Medical Officer Jan 02 '24 Sale 0.91 15,813 14,390 45,269 Jan 03 04:21 PM Cale Edgar B. GC & Corporate Secretary Jan 02 '24 Sale 0.91 15,813 14,390 45,995 Jan 03 04:19 PM King Simona Chief Financial Officer Jul 28 '23 Option Exercise 0.00 31,250 0 35,447 Aug 01 04:36 PM King Simona Chief Financial Officer Jul 28 '23 Sale 0.88 11,453 10,079 23,994 Aug 01 04:36 PM ORBIMED ADVISORS LLC 10% Owner Jun 28 '23 Buy 0.84 575,195 483,164 8,034,000 Jun 29 04:42 PM ORBIMED ADVISORS LLC 10% Owner Jun 27 '23 Buy 0.84 617,382 518,601 7,458,805 Jun 29 04:42 PM Fotopoulos Alexandros Chief Technical Officer Jun 16 '23 Sale 0.93 4,052 3,778 28,693 Jun 20 04:10 PM Fotopoulos Alexandros Chief Technical Officer Jun 15 '23 Option Exercise 0.00 12,500 0 32,745 Jun 20 04:10 PM King Simona Chief Financial Officer Apr 18 '23 Option Exercise 0.00 6,250 0 6,250 Apr 20 04:28 PM King Simona Chief Financial Officer Apr 18 '23 Sale 1.05 2,053 2,156 2,053 Apr 20 04:28 PM
Index RUT
P/E -
EPS (ttm) -3.89
Insider Own 55.49%
Shs Outstand 57.97M
Perf Week 15.94%
Market Cap 621.06M
Forward P/E -
EPS next Y -3.23
Insider Trans -10.32%
Shs Float 26.03M
Perf Month -1.48%
Income -201.59M
PEG -
EPS next Q -1.20
Inst Own 44.62%
Short Float 40.12%
Perf Quarter 14.69%
Sales 0.68M
P/S 913.32
EPS this Y -17.58%
Inst Trans 6.89%
Short Ratio 12.52
Perf Half Y 3.01%
Book/sh -1.26
P/B -
EPS next Y 30.00%
ROA -69.68%
Short Interest 10.44M
Perf Year 55.04%
Cash/sh 6.52
P/C 1.63
EPS next 5Y -
ROE -3489.00%
52W Range 6.07 - 17.02
Perf YTD 16.32%
Dividend Est. -
P/FCF -
EPS past 5Y -137.06%
ROI -55.18%
52W High -37.60%
Beta 0.63
Dividend TTM -
Quick Ratio 10.22
Sales past 5Y 0.00%
Gross Margin -8.80%
52W Low 75.10%
ATR (14) 0.90
Dividend Ex-Date -
Current Ratio 10.25
EPS Y/Y TTM 22.99%
Oper. Margin -24532.40%
RSI (14) 60.84
Volatility 12.51% 9.41%
Employees 452
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -29558.80%
Recom 1.25
Target Price 22.71
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -4.23%
Payout -
Rel Volume 1.06
Prev Close 11.05
Sales Surprise 70.12%
EPS Surprise -29.05%
Sales Q/Q -
Earnings Mar 07 BMO
Avg Volume 834.53K
Price 10.62
SMA20 12.86%
SMA50 25.40%
SMA200 1.38%
Trades
Volume 886,406
Change -3.89%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Reiterated
Needham
Buy
$23 → $26
Aug-09-23 Initiated
H.C. Wainwright
Buy
$28
May-11-23 Upgrade
Evercore ISI
In-line → Outperform
Mar-13-23 Initiated
Craig Hallum
Buy
$21
Oct-21-22 Initiated
Jefferies
Buy
$16
May-06-22 Downgrade
Evercore ISI
Outperform → In-line
May-12-21 Upgrade
Goldman
Sell → Neutral
$40 → $48
Feb-17-21 Initiated
BMO Capital Markets
Outperform
$63
Feb-02-21 Initiated
Guggenheim
Buy
$60
Jun-26-20 Downgrade
Goldman
Neutral → Sell
$34
Nov-20-19 Initiated
Evercore ISI
Outperform
Nov-19-19 Initiated
Needham
Buy
$40
Nov-19-19 Initiated
Jefferies
Buy
$32
Nov-19-19 Initiated
Goldman
Neutral
$32
Show Previous Ratings
Mar-26-24 08:00AM
Mar-08-24 03:05PM
01:57AM
(Thomson Reuters StreetEvents)
Mar-07-24 01:51PM
01:38PM
08:00AM
Loading…
08:00AM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Dec-14-23 08:00AM
Dec-06-23 08:00AM
Nov-28-23 08:00AM
Nov-09-23 09:34AM
08:00AM
Nov-01-23 05:00PM
08:00AM
Loading…
Oct-30-23 08:00AM
Oct-25-23 08:01AM
Sep-26-23 08:01AM
Sep-05-23 08:00AM
Aug-21-23 08:00AM
Aug-10-23 08:01AM
Aug-09-23 10:26AM
Aug-07-23 02:34PM
Jul-14-23 04:40PM
Jul-10-23 08:26AM
Jul-07-23 08:38AM
06:52AM
Jun-12-23 08:01AM
Jun-09-23 04:01PM
Jun-01-23 09:55AM
08:00AM
Loading…
08:00AM
May-27-23 09:07AM
May-26-23 09:55AM
May-25-23 09:55AM
May-23-23 07:41PM
04:01PM
04:00PM
May-10-23 08:00AM
May-09-23 08:00AM
Apr-12-23 08:00AM
07:07AM
Apr-10-23 06:44AM
Apr-05-23 08:35AM
Apr-04-23 08:00AM
Mar-27-23 09:55AM
Mar-07-23 12:00PM
Feb-28-23 08:00AM
Feb-10-23 08:53AM
07:59AM
Feb-09-23 04:01PM
Jan-28-23 01:58PM
Jan-24-23 09:02AM
Jan-13-23 06:56AM
Jan-08-23 06:00PM
Jan-06-23 05:02AM
Jan-05-23 11:31AM
Jan-04-23 09:17AM
Jan-03-23 04:01PM
Nov-08-22 05:00PM
Nov-03-22 08:30AM
Nov-01-22 08:00AM
Oct-24-22 08:00AM
Oct-23-22 12:01PM
Oct-18-22 08:00AM
Sep-26-22 08:00AM
Sep-07-22 08:15AM
Aug-17-22 09:16AM
Aug-02-22 08:00AM
Jun-01-22 08:15AM
May-25-22 08:00AM
May-24-22 12:15PM
May-17-22 08:01AM
May-11-22 10:54AM
May-10-22 08:00AM
May-04-22 08:01AM
May-03-22 05:40PM
Apr-26-22 08:00AM
Apr-13-22 02:10PM
Apr-01-22 08:01AM
Mar-22-22 08:02AM
Mar-14-22 08:02AM
Mar-01-22 04:04PM
Feb-11-22 08:52PM
Feb-09-22 04:04PM
Nov-23-21 04:00PM
Nov-12-21 04:30PM
Nov-10-21 08:32PM
Nov-08-21 08:00AM
Oct-27-21 09:47PM
Oct-26-21 04:01PM
Oct-24-21 03:30PM
Oct-21-21 08:00AM
Oct-18-21 12:14PM
10:28AM
08:20AM
07:00AM
Oct-11-21 03:55PM
Sep-27-21 03:50PM
08:00AM
Sep-20-21 08:00AM
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Curran Terrie President and Chief Executive Mar 22 '24 Sale 9.11 16,851 153,513 410,784 Mar 26 04:05 PM TAKEDA PHARMACEUTICAL CO LTD 10% Owner Jan 24 '24 Sale 8.10 3,703,703 29,999,994 3,755,583 Jan 25 06:13 AM Henderson Molly CFO and CBO Jan 19 '24 Sale 7.75 6,307 48,900 98,698 Jan 22 08:22 PM Henderson Molly CFO and CBO Nov 20 '23 Sale 7.24 2,127 15,403 103,061 Nov 21 04:40 PM Parikh Asit Director Nov 08 '23 Buy 7.80 2,500 19,500 55,000 Nov 08 07:56 PM Parikh Asit Director Nov 07 '23 Buy 7.76 4,000 31,040 52,500 Nov 08 07:56 PM Parikh Asit Director Nov 06 '23 Buy 8.04 1,000 8,040 48,500 Nov 08 07:56 PM Henderson Molly CFO and CBO Nov 01 '23 Sale 8.88 12,492 110,871 105,188 Nov 03 04:55 PM Henderson Molly CFO and CBO Jun 02 '23 Sale 11.41 1,960 22,368 68,506 Jun 05 06:32 PM Henderson Molly CFO and CBO May 22 '23 Sale 12.87 2,110 27,165 70,466 May 23 12:15 PM Nabulsi Azmi Chief Operating Officer Apr 11 '23 Buy 8.26 10,000 82,600 99,567 Apr 11 04:05 PM Parikh Asit Director Apr 10 '23 Buy 7.55 1,000 7,550 23,500 Apr 11 04:05 PM Curran Terrie President and Chief Executive Apr 06 '23 Buy 7.82 12,919 101,025 188,290 Apr 07 03:19 PM Henderson Molly CFO and CBO Apr 06 '23 Sale 7.27 3,439 25,002 72,576 Apr 07 03:18 PM
Index RUT
P/E -
EPS (ttm) -4.03
Insider Own 21.46%
Shs Outstand 46.72M
Perf Week -3.53%
Market Cap 1.17B
Forward P/E 40.31
EPS next Y 0.62
Insider Trans -0.31%
Shs Float 36.61M
Perf Month -13.05%
Income -160.91M
PEG -
EPS next Q -0.36
Inst Own 91.35%
Short Float 22.23%
Perf Quarter -16.43%
Sales 186.37M
P/S 6.28
EPS this Y 75.39%
Inst Trans 11.41%
Short Ratio 13.58
Perf Half Y -18.44%
Book/sh 5.32
P/B 4.72
EPS next Y 164.27%
ROA -32.20%
Short Interest 8.14M
Perf Year 9.74%
Cash/sh 6.14
P/C 4.09
EPS next 5Y -
ROE -82.37%
52W Range 21.83 - 35.56
Perf YTD -14.91%
Dividend Est. -
P/FCF -
EPS past 5Y -39.57%
ROI -28.95%
52W High -29.36%
Beta 1.14
Dividend TTM -
Quick Ratio 4.19
Sales past 5Y 88.90%
Gross Margin 75.98%
52W Low 15.04%
ATR (14) 1.20
Dividend Ex-Date -
Current Ratio 4.45
EPS Y/Y TTM -0.28%
Oper. Margin -57.22%
RSI (14) 36.30
Volatility 3.75% 4.75%
Employees 264
Debt/Eq 1.24
Sales Y/Y TTM 141.85%
Profit Margin -86.33%
Recom 1.11
Target Price 50.78
Option/Short Yes / Yes
LT Debt/Eq 1.23
EPS Q/Q 28.44%
Payout -
Rel Volume 0.71
Prev Close 25.12
Sales Surprise 2.49%
EPS Surprise -162.39%
Sales Q/Q 149.24%
Earnings Feb 28 AMC
Avg Volume 599.15K
Price 25.12
SMA20 -7.80%
SMA50 -8.35%
SMA200 -11.34%
Trades
Volume 424,360
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-18-23 Reiterated
H.C. Wainwright
Buy
$60 → $58
Nov-20-23 Resumed
JP Morgan
Overweight
$37
Nov-13-23 Initiated
Morgan Stanley
Overweight
$60
Oct-24-23 Initiated
Cantor Fitzgerald
Overweight
$50
Oct-17-23 Resumed
Evercore ISI
Outperform
$62
Sep-20-23 Initiated
JMP Securities
Mkt Outperform
$70
Sep-01-22 Initiated
Citigroup
Buy
$38
Sep-20-21 Initiated
JP Morgan
Overweight
$30
Aug-07-20 Upgrade
Raymond James
Outperform → Strong Buy
$28 → $48
Aug-03-20 Initiated
H.C. Wainwright
Buy
$52
Jul-31-20 Initiated
Piper Sandler
Overweight
$77
Jun-25-20 Initiated
Robert W. Baird
Outperform
$30
Aug-12-19 Initiated
ROTH Capital
Buy
$33
Aug-12-19 Initiated
Raymond James
Outperform
$28
Aug-12-19 Initiated
Guggenheim
Buy
$18
Aug-12-19 Initiated
Evercore ISI
Outperform
Aug-12-19 Initiated
Citigroup
Buy
$21
Show Previous Ratings
Mar-25-24 11:46PM
07:00AM
Mar-15-24 09:32AM
Mar-13-24 06:00PM
Mar-08-24 07:30PM
08:00AM
Loading…
Mar-05-24 08:00AM
Feb-29-24 11:34AM
09:49AM
08:30AM
Feb-28-24 05:35PM
04:38PM
04:03PM
Feb-21-24 04:05PM
Feb-09-24 09:15PM
Feb-05-24 07:00AM
11:44AM
Loading…
Jan-23-24 11:44AM
Jan-19-24 09:30PM
Jan-16-24 08:30AM
Jan-15-24 04:03AM
Jan-10-24 07:00PM
Jan-08-24 08:30AM
Jan-03-24 08:45AM
Dec-18-23 01:05PM
(Associated Press Finance) -15.87%
08:37AM
08:30AM
Dec-08-23 07:30PM
Nov-30-23 09:45AM
Nov-20-23 04:05PM
Nov-13-23 02:00PM
Nov-10-23 05:30PM
09:10AM
Loading…
Nov-06-23 09:10AM
Nov-03-23 08:30AM
Nov-02-23 07:13PM
04:05PM
Oct-30-23 10:00AM
08:30AM
Oct-27-23 08:45AM
Oct-17-23 04:30PM
Oct-11-23 04:52PM
Oct-10-23 08:00PM
Oct-07-23 05:00PM
Oct-02-23 08:30AM
Sep-26-23 08:30AM
Sep-21-23 08:30AM
Sep-15-23 03:05PM
08:30AM
06:01AM
Sep-14-23 01:15PM
Sep-13-23 01:01PM
Sep-11-23 10:07AM
Sep-08-23 11:30PM
Sep-06-23 11:19AM
08:30AM
Sep-05-23 08:30AM
08:30AM
Aug-10-23 07:00PM
Aug-03-23 05:25PM
04:05PM
Jul-27-23 04:05PM
Jul-25-23 05:12PM
08:30AM
Jul-20-23 08:18AM
Jul-18-23 10:48AM
(American City Business Journals)
Jul-17-23 02:18PM
08:00AM
08:00AM
Jul-10-23 08:00PM
Jun-29-23 09:27AM
Jun-23-23 12:00PM
Jun-14-23 08:30AM
Jun-09-23 09:30PM
Jun-07-23 08:30AM
Jun-02-23 08:49AM
May-19-23 07:00AM
May-18-23 08:30AM
May-17-23 08:30AM
May-11-23 08:30AM
May-10-23 09:00PM
May-09-23 02:59PM
May-06-23 08:05AM
May-04-23 06:05PM
04:02PM
May-01-23 10:00AM
Apr-27-23 04:02PM
10:02AM
Apr-25-23 05:44AM
Apr-18-23 06:15AM
Apr-13-23 12:15AM
Apr-12-23 07:00AM
06:59AM
Apr-10-23 08:30PM
Apr-06-23 08:30AM
Apr-05-23 08:30AM
Apr-02-23 11:36AM
Mar-31-23 06:39AM
Mar-15-23 09:05AM
Mar-14-23 08:30AM
Mar-11-23 06:40AM
Mar-10-23 08:30PM
Mar-09-23 12:27PM
(Thomson Reuters StreetEvents)
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 27 '24 Buy 24.80 2,000 49,600 14,000 Mar 27 08:47 PM Radovich Peter PRESIDENT AND COO Mar 25 '24 Sale 25.80 4,303 111,017 29,013 Mar 25 05:41 PM BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 18 '24 Buy 25.80 2,000 51,600 12,000 Mar 18 05:34 PM Peetz Christopher CHIEF EXECUTIVE OFFICER Feb 02 '24 Sale 26.19 6,013 157,491 104,112 Feb 05 09:04 PM Radovich Peter PRESIDENT AND COO Feb 02 '24 Sale 26.19 1,790 46,883 34,695 Feb 05 09:05 PM Vig Pamela CHIEF SCIENTIFIC OFFICER Feb 02 '24 Sale 26.19 1,214 31,797 28,691 Feb 05 09:12 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Feb 02 '24 Sale 26.19 847 22,184 104,407 Feb 05 09:10 PM Howe Jolanda SVP, GLOBAL CONTROLLER Feb 02 '24 Sale 26.19 735 19,251 1,759 Feb 02 09:28 PM Peetz Christopher PRESIDENT AND CEO Jan 08 '24 Sale 28.03 5,209 146,033 110,125 Jan 09 08:12 PM Radovich Peter CHIEF OPERATING OFFICER Jan 08 '24 Sale 28.03 1,408 39,473 36,485 Jan 09 08:28 PM Vig Pamela HEAD OF RESEARCH & DEVELOPMENT Jan 08 '24 Sale 28.03 1,408 39,472 29,905 Jan 09 08:21 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Jan 08 '24 Sale 28.04 1,019 28,568 105,254 Jan 09 08:25 PM Howe Jolanda SVP, GLOBAL CONTROLLER Jan 08 '24 Sale 28.04 528 14,803 722 Jan 09 08:09 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Option Exercise 2.94 2,500 7,350 2,500 Dec 06 05:16 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Sale 32.40 2,500 81,000 0 Dec 06 05:16 PM GREY MICHAEL G Director Sep 14 '23 Option Exercise 2.94 14,216 41,738 14,216 Sep 14 07:33 PM GREY MICHAEL G Director Sep 14 '23 Sale 32.00 14,216 454,912 0 Sep 14 07:33 PM GREY MICHAEL G Director Sep 13 '23 Option Exercise 2.94 392 1,151 392 Sep 14 07:33 PM Heron Patrick J Director Sep 13 '23 Buy 31.02 2,625 81,425 159,053 Sep 15 04:56 PM GREY MICHAEL G Director Sep 13 '23 Sale 32.00 392 12,544 0 Sep 14 07:33 PM Heron Patrick J Director Sep 12 '23 Buy 30.60 3,750 114,764 156,428 Sep 13 04:39 PM BJERKHOLT ERIC Chief Financial Officer Sep 11 '23 Buy 29.65 10,000 296,492 10,000 Sep 12 06:23 PM Heron Patrick J Director Sep 11 '23 Buy 30.30 4,687 142,027 152,678 Sep 13 04:39 PM Heron Patrick J Director Aug 31 '23 Buy 26.25 147,991 3,884,764 147,991 Sep 05 12:51 PM Howe Jolanda SVP, Global Controller Aug 25 '23 Sale 26.23 3,459 90,743 0 Aug 28 04:30 PM Peetz Christopher President and CEO Jul 03 '23 Sale 25.65 5,498 141,005 115,334 Jul 05 07:30 PM Radovich Peter Chief Operating Officer Jul 03 '23 Sale 25.65 1,425 36,546 37,675 Jul 05 07:47 PM Vig Pamela Head of Research & Development Jul 03 '23 Sale 25.65 1,425 36,546 30,786 Jul 05 07:35 PM Longpre Lara Chief Development Officer Jul 03 '23 Sale 25.65 1,004 25,749 105,839 Jul 05 07:37 PM Howe Jolanda SVP, Global Controller Jul 03 '23 Sale 25.65 915 23,467 3,459 Jul 05 07:33 PM GREY MICHAEL G Director Jun 08 '23 Option Exercise 2.94 14,608 42,889 14,608 Jun 09 04:20 PM GREY MICHAEL G Director Jun 08 '23 Sale 29.00 14,608 423,632 0 Jun 09 04:20 PM GREY MICHAEL G Director May 03 '23 Option Exercise 2.94 14,608 42,889 14,608 May 04 09:58 PM GREY MICHAEL G Director May 03 '23 Sale 28.00 14,608 409,024 0 May 04 09:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite